Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
146.80    0.60 (0.41%)
Bid:
146.80
Ask:
148.00
Spread: 1.20 (0.817%)
Market Cap: £250.83m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Acquisition

2 Sep 2010 07:00

RNS Number : 0180S
McBride PLC
02 September 2010
 



2 September 2010

 

McBride plc

 

McBride plc announces the acquisition of Dermacol a.s., a manufacturer of skincare products based in the Czech Republic.

 

McBride plc ("McBride"), Europe's leading provider of Private Label Household and Personal Care products, today announces the acquisition of a 70% interest in Dermacol a.s. ("the Company"), a privately owned, Czech-based manufacturer of skincare products for an expected consideration of around CZK240 million (£8 million) from its parent company Alphaduct a.s. ("Alphaduct"). McBride has also agreed to purchase the remaining 30% of the shares in late 2017 for a consideration based on the Company's operating profit in the 2017 financial year.

 

Acquisition highlights

 

·; Provides McBride with an established private label product range in the largest sector of the European Personal Care market.

 

·; Creates the base for future growth in our skincare business.

 

·; Expands our presence in the growing Central European markets in a low-cost location.

 

Information on Dermacol a.s.

 

Dermacol a.s. is a manufacturer of skincare products, including face creams, skin cleansers, sun care products, body lotions, hand creams and foot creams. Its sales are evenly split between private label products for supermarkets and pharmacy chains and branded products for Alphaduct, which are sold in the Czech Republic and certain other markets. As part of the acquisition agreement, Alphaduct remains the owner of the Dermacol brand and trademarks and it will continue the distribution and marketing of its branded products. Alphaduct has entered into an agreement with the Company to purchase a minimum volume of product on a cost plus basis until 2018.

 

The Company has one factory, which is based near Brno in the Czech Republic and employs over 100 people. It is a modern, well invested factory with significant capacity for expansion. The factory meets ISO 9001 standards and GMP standards required by customers.

 

During the year ended 31 December 2009, the Company reported profit before tax of CZK24 million (£0.8 million). At 31 December 2009, gross assets were CZK 312 million (£10.4 million).

 

Terms of the acquisition

 

The consideration for the initial 70% of the Company's shares comprises:

i. a first payment today of CZK 70 million in cash (£2.3 million); plus

ii. a second payment of CZK 54 million in cash (£1.9 million) payable in August 2011; plus

iii. a further five payments, in cash, payable from 2013 to 2017 inclusive, based on the Company's sales during the period.

 

The expected total consideration of CZK240 million (£8 million) for the initial 70% of shares of the Company will be made from existing Group resources.

 

The remaining 30% of the shares in the Company will be acquired by McBride following the end of the 2017 fiscal year based on the Company's operating profits in that year. The total consideration for the company cannot exceed CZK650 million (£21.7 million).

 

Strategic rationale for the acquisition

 

McBride's strategy is to lead the development of private label household and personal care products in Europe through a focus on organic growth, supplemented by selected acquisitions. Skincare represents 33% of the total European Personal Care market, and is estimated to be worth over 1.1 billion Euros at RSP. Growth of private label has exceeded total personal care growth in the last four years.

 

The Company provides McBride with a range of skincare development and manufacturing capabilities which is highly complementary to its current personal care range. It also provides McBride with a modern, flexible manufacturing plant in a cost competitive region of Europe. The Company will contribute to the significant private label skincare sales forecast for the McBride group, in particular in the UK, France and Germany.

 

Commenting on the acquisition, McBride's chief executive Chris Bull, said:

 

"I am delighted that we have been able to acquire such a high quality skincare company. It is consistent with our stated corporate strategy and provides McBride with a full range of products to create private label skincare ranges for our customers."

 

 

For further information please contact:

 

McBride plc

Chris Bull, Chief Executive

0207 539 7850

Richard Armitage, Finance Director

0207 539 7851

Financial Dynamics

Edward Bridges/Marc Cohen,

020 7831 3113

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQKKDDQFBKDCCK
Date   Source Headline
2nd May 20249:21 amRNSHolding(s) in Company
30th Apr 20247:00 amRNSTrading Update
8th Apr 202411:24 amRNSHolding(s) in Company
8th Apr 202411:22 amRNSHolding(s) in Company
5th Apr 20249:53 amRNSHolding(s) in Company
28th Mar 20243:20 pmRNSDirector/PDMR Shareholding
25th Mar 20241:52 pmRNSDirector/PDMR Shareholding
13th Mar 20247:00 amRNSCapital Markets Day
28th Feb 20242:30 pmRNSDirector/PDMR Shareholding
27th Feb 20247:00 amRNSHalf-year Report
16th Jan 20247:00 amRNSTrading Update
13th Dec 20231:47 pmRNSDirector/PDMR Shareholding
20th Nov 20235:55 pmRNSDirector/PDMR Shareholding
20th Nov 20235:39 pmRNSResult of AGM
20th Nov 20237:00 amRNSAGM Trading Update
25th Oct 202310:22 amRNSTermination of ‘upside sharing’ mechanism
19th Oct 20237:00 amRNSTrading Update
17th Oct 20235:42 pmRNSPosting of ARA and Notice of AGM
4th Oct 20235:24 pmRNSVesting of RSU Awards
29th Sep 20237:00 amRNSDirector/PDMR Shareholding
22nd Sep 20235:33 pmRNSDirector/PDMR Shareholding
21st Sep 202310:54 amRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSFinal Results
14th Jul 20237:00 amRNSFull year trading update
13th Jun 20237:00 amRNSDirector/PDMR Shareholding
31st May 20235:31 pmRNSDirectorate Change
25th May 20239:38 amRNSDirector Declaration
2nd May 20237:00 amRNSDirector/PDMR Shareholding
25th Apr 20237:00 amRNSTrading Update
11th Apr 20232:08 pmRNSDirector/PDMR Shareholding
3rd Apr 20232:39 pmRNSDirector/PDMR Shareholding
31st Mar 202312:27 pmRNSDirector/PDMR Shareholding
21st Mar 20235:59 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNSHalf-year Report
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20238:46 amRNSDirector Declaration
17th Jan 20237:00 amRNSTrading Update
11th Jan 20239:01 amRNSDirector Declaration
22nd Dec 20224:23 pmRNSDirector/PDMR Shareholding
13th Dec 20222:51 pmRNSDirector/PDMR Shareholding
16th Nov 20224:42 pmRNSAGM Statement
16th Nov 20227:00 amRNSAGM Trading Update
17th Oct 20227:00 amRNSAnnual Report 2022 and Annual General Meeting 2022
5th Oct 20225:55 pmRNSDirector/PDMR Shareholding
3rd Oct 20225:07 pmRNSRedemption of B Shares
29th Sep 202212:49 pmRNSFinal Results
29th Sep 202211:51 amRNSAmended Financing Agreement
29th Sep 20227:00 amRNSPreliminary results timing
6th Sep 20222:51 pmRNSBoard Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.